Haemostasis pp 265-272 | Cite as

Anti-factor Xa (Anti-Xa) Assay

  • Fiona Newall
Part of the Methods in Molecular Biology book series (MIMB, volume 992)


The anti-factor Xa (anti-Xa) assay is a functional assay that facilitates the measurement of antithrombin (AT)-catalyzed inhibition of factor Xa by unfractionated heparin (UFH) and direct inhibition of factor Xa by low-molecular-weight heparin (LMWH) (Kitchen, Br J Haematol 111:397–406, 2000; Walenga et al., Semin Thromb Hemost 11:17–25, 1985; Levine et al., Arch Intern Med 154:49–56, 1994; Barrowcliffe et al., J Pharm Biomed Anal 7:217–226, 1989; Triplett, Ther Drug Monit 1:173–197, 1979; Nelson, Clin Lab Sci 12:359–364, 1999; Laffan and Manning, Dacie and Lewis: practical haematology, Churchill Livingstone, London, pp 465–479, 2001; Olson et al., Arch Pathol Lab Med 122:782–798, 1998). Whilst automated methods for the determination of the abilities of UFH and LMWH to inhibit factor Xa have been available since the 1970s, their cost was viewed to prohibit their broad use in the clinical management of UFH and LMWH until relatively recently. The anti-Xa assay can also be used to guide the determination of therapeutic APTT ranges in the clinical management of UFH (Hirsh and Raschke, Chest 126:188S–203S, 2004). As a result, the anti-Xa assay is commonly viewed as a heparin assay, despite the fact that it actually provides a measure of UFH effect as opposed to a measure of UFH concentration.

Key words

Anti-Xa assay Chromogenic test Heparin monitoring LMWH monitoring 


  1. 1.
    Olson J, Arkin C, Brandt J, Cunningham M, Giles A, Koepke J, Witte D (1998) College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 122:782–798PubMedGoogle Scholar
  2. 2.
    Laffan M, Manning R (2001) Laboratory control of anticoagulant, thrombolytic and anti-platelet therapy (Chapter 18). In: Lewis S, Bain B, Bates I (eds) Dacie and Lewis: practical haematology, 9th edn. Churchill Livingstone, London, pp 465–479Google Scholar
  3. 3.
    Levine M, Hirsh J, Gent M, Turpie A, Cruisckshank M, Weitz J, Anderson D, Johnson M (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154:49–56PubMedCrossRefGoogle Scholar
  4. 4.
    Hirsh J, Raschke R (2004) Heparin and ­low-molecular-weight heparin. Chest 126: 188S–203SPubMedCrossRefGoogle Scholar
  5. 5.
    Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, DeRosa L, Hamilton S, Ragg P, Robinson S, Auldist A, Crock C, Rowlands S (2006) Developmental haemostasis: Impact for clinical haemostasis laboratories. Thromb Haemost 95:362–372PubMedGoogle Scholar
  6. 6.
    Kovacs M, Keeney M, MacKinnon K, Boyle E (1999) Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 21:55–60PubMedCrossRefGoogle Scholar
  7. 7.
    Kitchen S, Theaker J, Preston F (2000) Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis 11:137–144PubMedGoogle Scholar
  8. 8.
    Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennet M, Shann F, Lane G, Ross-Smith M, Monagle P (2007) Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate? Thromb Res 120:347–351PubMedCrossRefGoogle Scholar
  9. 9.
    Ignjatovic V, Summerhayes R, Than J, Gan A, Monagle P (2006) Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. J Thromb Haemost 4:2280–2282PubMedCrossRefGoogle Scholar
  10. 10.
    Kitchen S (2000) Problems in laboratory monitoring of heparin dosage. Br J Haematol 111:397–406PubMedCrossRefGoogle Scholar
  11. 11.
    Walenga J, Fareed J, Hoppensteadt D (1985) In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight heparin. Semin Thromb Hemost 11:17–25PubMedCrossRefGoogle Scholar
  12. 12.
    Barrowcliffe T, Mulloy B, Johnson E, Thomas D (1989) The anticoagulant activity of heparin: measurement and relationship to chemical structure. J Pharm Biomed Anal 7:217–226PubMedCrossRefGoogle Scholar
  13. 13.
    Triplett D (1979) Heparin: biochemistry, therapy, and laboratory monitoring. Ther Drug Monit 1:173–197PubMedCrossRefGoogle Scholar
  14. 14.
    Nelson D (1999) Current considerations in the use of the APTT in monitoring unfractionated heparin. Clin Lab Sci 12:359–364PubMedGoogle Scholar
  15. 15.
    Monagle P, Chan A, Massicotte P, Chalmers E, Michelson A (2004) Antithrombotic therapy in children. Chest 126:645S–687SPubMedCrossRefGoogle Scholar
  16. 16.
    Ignjatovic V, Furmedge J, Newall F, Chan A, Berry L, Fong C, Cheng K, Monagle P (2006) Age-related differences in heparin response. Thromb Res 118:741–745PubMedCrossRefGoogle Scholar
  17. 17.
    Chan A, Black L, Ing C, Brandao L, Williams S (2007) Utility of aPTT in monitoring unfractionated heparin in children. Thromb Res 122:135–136PubMedCrossRefGoogle Scholar
  18. 18.
    Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Lau A, Mitchell L (2007) Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica 92:554–557PubMedCrossRefGoogle Scholar
  19. 19.
    Newall F, Ignjatovic V, Johnston L, Summerhayes R, Lane G, Cranswick N, Monagle P (2010) Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin. Thromb Haemost 103:1085–1090PubMedCrossRefGoogle Scholar
  20. 20.
    Standards N (ed) (1998) Collection, transport and processing of blood specimens for coagulation testing and general performance of coagulation assays. NCCLS, Wayne, PAGoogle Scholar
  21. 21.
    Reneke J, Etzell J, Leslie S (1998) Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2 %) citrate anticoagulant. Am J Clin Pathol 109:754–757PubMedGoogle Scholar
  22. 22.
    Rose VL, Dermott SC, Murray BF, McIver MM, High KA (1993) Decentralized testing for PT and activated PTT using a dry chemistry portable analyzer. Arch Pathol Lab Med 117:611–617PubMedGoogle Scholar
  23. 23.
    Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennet M, Shann F, Lane G, Ross-Smith M, Monagle P (2006) Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate? J Thromb Haemost 120:347–351Google Scholar

Copyright information

© Humana Press 2013

Authors and Affiliations

  • Fiona Newall
    • 1
    • 2
    • 3
  1. 1.Department of Clinical HaematologyThe Royal Children’s HospitalMelbourneAustralia
  2. 2.Department of PaediatricsThe University of MelbourneMelbourneAustralia
  3. 3.Department of NursingThe University of MelbourneMelbourneAustralia

Personalised recommendations